Go Pro
NASDAQ:CELU

Celularity Q1 2024 Earnings Report

Celularity logo
$1.38 +0.03 (+2.22%)
Closing price 04:00 PM Eastern
Extended Trading
$1.36 -0.02 (-1.81%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Celularity EPS Results

Actual EPS
-$1.03
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Celularity Revenue Results

Actual Revenue
$14.68 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Celularity Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Wednesday, October 16, 2024
Conference Call Time
3:30AM ET

Upcoming Earnings

Celularity's Q2 2026 earnings is estimated for Friday, November 13, 2026, based on past reporting schedules

Earnings Documents

Celularity Earnings Headlines

Ticker Revealed: Pre-IPO Access to "Next Elon Musk" Company
We’ve found The Next Elon Musk… and what we believe to be the next Tesla. It’s already racked up $26 billion in government contracts. Peter Thiel just bet $1 Billion on it.tc pixel
Celularity (NASDAQ:CELU) Releases Quarterly Earnings Results
Celularity Inc. ernennt Naveen Jain zum Verwaltungsratsmitglied
See More Celularity Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Celularity? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Celularity and other key companies, straight to your email.

About Celularity

Celularity (NASDAQ:CELU) is a biotechnology company developing allogeneic cell therapies and biomaterial products derived from human placenta. The company’s research focuses on using placental cells and tissues to address unmet needs in oncology, immune-mediated diseases and regenerative medicine.

Celularity’s therapeutic pipeline has included CYNK-001, an off-the-shelf natural killer cell therapy being investigated for certain blood cancers, as well as other engineered and unmodified placental-derived cell programs. The company has also developed placental-derived biomaterial products intended to support wound care and tissue repair.

Founded in 2016, Celularity is headquartered in Florham Park, New Jersey. The company was founded by Robert J. Hariri, M.D., Ph.D., who has served in senior leadership roles, including chief executive officer and chairman. Its products and clinical programs are intended for use in the United States and other markets where regulatory authorization or clinical development is available.

View Celularity Profile